

**AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 14: TRAINING IN CARE OF ADULT PATIENTS WITH CONGENITAL HEART DISEASE**

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Carole A. Warnes (Chair)	Mayo Clinic—Director, Adult Congenital Heart Disease Clinic; Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> <li>Actelion Pharmaceuticals*</li> </ul>	None
Ami B. Bhatt	Massachusetts General Hospital, Cardiology Division—Director, Adult Congenital Heart Disease Program	None	None	None	None	None	None
Curtis J. Daniels	The Ohio State University—Professor, Internal Medicine and Pediatrics	None	None	None	None	<ul style="list-style-type: none"> <li>Actelion</li> </ul>	None
Linda D. Gillam	Morristown Medical Center—Chair, Department of CV Medicine	None	None	None	<ul style="list-style-type: none"> <li>Edwards Lifesciences*</li> <li>Medtronic*</li> <li>Middlepeak*</li> </ul>	<ul style="list-style-type: none"> <li>Circulation Imaging</li> <li>Edwards Lifesciences*</li> <li>National Board of Echocardiography*</li> </ul>	None
Karen K. Stout	University of Washington—Director, Adult Congenital Heart Disease Program	None	None	None	None	None	None

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\* No financial benefit.